Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Authors

Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
Thomas Bieber (ORCID: https://orcid.org/0000-0002-8800-3817)
D. Staumont‐Sallé (ORCID: https://orcid.org/0000-0002-4780-4212)
Irene Hernández‐Martín (ORCID: https://orcid.org/0000-0001-9620-0485)
Patrick M. Brunner (ORCID: https://orcid.org/0000-0002-3488-3345)
J.M. Carrascosa (ORCID: https://orcid.org/0000-0003-4266-0771)
Francisco José Rebollo Laserna (ORCID: https://orcid.org/0000-0003-3651-3687)
Herwig Koppensteiner
Chao Ji (ORCID: https://orcid.org/0000-0002-1913-9702)
Bob Geng (ORCID: https://orcid.org/0000-0002-4618-4445)
Pinaki Biswas (ORCID: https://orcid.org/0009-0009-3494-4142)
Claire Feeney (ORCID: https://orcid.org/0000-0003-4605-6571)

Institutions

Fujian Medical University (CN)
Oregon Health & Science University (US)
Pfizer (United States) (US)
Pfizer (United Kingdom) (GB)
George Washington University (US)
UC San Diego Health System (US)
Centre Hospitalier Universitaire de Lille (FR)
University of California San Diego (US)
Lille’s Cardiology Hospital (FR)
University Hospital of Zurich (CH)
Vienna Consulting Engineers (Austria) (AT)
CK-CARE (CH)
First Affiliated Hospital of Fujian Medical University (CN)
Lille Inflammation Research International Center (FR)
Pfizer (Spain) (ES)
Hospital Universitari Germans Trias i Pujol (ES)
Pfizer (Austria) (AT)
Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-09-23
DOI: https://doi.org/10.1007/s13555-025-01516-w
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Sanofi
Gilead Sciences
Biogen
Celgene
CSL Behring
Regeneron Pharmaceuticals
Les Laboratories Pierre Fabre
Mylan
Incyte
Yuhan
Horizon Therapeutics
EQRx
Glenmark Pharmaceuticals
Galderma
Medac
LG Chem
LEO Pharma
Genentech
Samsung
Sanofi Genzyme
Daiichi Sankyo Europe

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Jonathan I. Silverberg, Eric L. Simpson, Thomas Bieber, D. Staumont‐Sallé et al.

Sep 23, 2025

Dermatology and Therapy

Dermatology and Skin Diseases

article

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Jonathan I. Silverberg, Eric L. Simpson, Thomas Bieber, D. Staumont‐Sallé, Irene Hernández‐Martín, Patrick M. Brunner, J.M. Carrascosa, Francisco José Rebollo Laserna, Herwig Koppensteiner, Chao Ji, Bob Geng, Pinaki Biswas, Claire Feeney

September 23, 2025article en

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 15(11)

Fujian Medical University (CN), Oregon Health & Science University (US), Pfizer (United States) (US), Pfizer (United Kingdom) (GB), George Washington University (US), UC San Diego Health System (US), Centre Hospitalier Universitaire de Lille (FR), University of California San Diego (US), Lille’s Cardiology Hospital (FR), University Hospital of Zurich (CH), Vienna Consulting Engineers (Austria) (AT), CK-CARE (CH), First Affiliated Hospital of Fujian Medical University (CN), Lille Inflammation Research International Center (FR), Pfizer (Spain) (ES), Hospital Universitari Germans Trias i Pujol (ES), Pfizer (Austria) (AT), Icahn School of Medicine at Mount Sinai (US)

Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Biogen, Celgene, CSL Behring, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Mylan, Incyte, Yuhan, Horizon Therapeutics, EQRx, Glenmark Pharmaceuticals, Galderma, Medac, LG Chem, LEO Pharma, Genentech, Samsung, Sanofi Genzyme, Daiichi Sankyo Europe

Openalex Percentile: Top 54%

Dermatology and Skin Diseases

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.